Attralus Closes $56 Million Financing
06 févr. 2024 07h00 HE
|
Attralus, Inc
Attralus, Inc. today announced that it has closed a $56 million financing.
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
07 nov. 2023 07h00 HE
|
Attralus, Inc
124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies.124I-evuzamitide detects multiple types of systemic...
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
02 oct. 2023 07h00 HE
|
Attralus, Inc
Attralus announced eight data presentations related to the use of 124I-evuzamitide (AT-01), the company's pan-amyloid binding imaging agent, at ASNC 2023.
Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
03 avr. 2023 07h00 HE
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
19 déc. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
17 nov. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
17 oct. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
12 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates significantly higher left ventricular uptake...
Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis
08 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organsSensitivity in those with previously diagnosed cardiac disease was 100%...
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
07 sept. 2022 07h00 HE
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...